Programme Thesis
The Novo Nordisk Fonden Open Competition Grants fund innovative research in health and life sciences, including biomedicine, biotechnology, and data science, to advance scientific knowledge and address unmet medical needs. The programme exists to support high-risk, high-reward projects from individual researchers or small collaborations, with a strong emphasis on Danish and European research environments.
Selection Criteria
- Scientific excellence and novelty of the research question
- Feasibility and robustness of the methodology
- Relevance to health and life sciences (e.g., addiction, pharmacology, computational biology)
- Applicant's track record and qualifications (publications, patents, independent work)
- Potential for impact (translational, clinical, or societal)
- Fit with Foundation's strategic areas (e.g., infectious diseases, data science, clinical medicine)
- Eligibility: Main applicant must be a registered nurse (noted as a requirement; this is a critical gotcha for Eniola)
Past Winners / Cohort Profiles
Past winners typically include established researchers at Danish universities (e.g., University of Copenhagen, Aarhus University) or hospitals, often with PhDs and postdoctoral experience. Named examples are not provided on the page, but the profile is a mid-career to senior scientist with a strong publication record in biomedicine or biotechnology. Early-career and independent researchers are less common unless they have a formal affiliation with a Danish institution.
Ideal Candidate Fingerprint
The platonic ideal applicant is a registered nurse or a researcher with a clinical background, affiliated with a Danish or European university, holding a PhD or equivalent, with a proven track record of high-impact publications in health or life sciences. The project should be clearly aligned with the Foundation's focus areas, such as infectious diseases, data science, or clinical medicine, and demonstrate potential for translation or societal benefit.
Recommended Framing
Eniola should frame their CCT model as a novel, data-driven approach to addiction treatment that bridges computational neuroscience and pharmacology, with strong proof-of-concept (85.8% reduction in encoding probability) and endorsements from leading neuroscientists (Berridge, Gershman, Daw). However, the critical red flag is the requirement that the main applicant be a registered nurse—Eniola is a pharmacist, not a nurse. To proceed, Eniola must either collaborate with a registered nurse as co-PI or seek a different programme. If pursuing this grant, the angle should emphasize the interdisciplinary, translational potential of CCT for clinical addiction therapy, leveraging the strong computational and pharmacological validation.
Watch Out
The programme explicitly states 'The main applicant must be a registered nurse'—Eniola is a pharmacist, not a nurse, making them ineligible as sole PI. Additionally, the programme is highly competitive and typically requires a PhD or equivalent, which Eniola does not yet have. The lack of a formal affiliation with a Danish or European institution (Eniola is independent in Lagos) is a further disadvantage. The rolling deadline and broad scope may dilute the application's fit.